Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$136.0MMiss by $22.2M
EPS-$1.84Miss by $0.35
Revenue estimate$158.2M
EPS estimate-$1.49

Next report

Aug 4, 2026 (In 5 days)
Revenue estimate$183.1M
EPS estimate-$1.21

Financials

Q1 2026

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$2.65B+1.5%
P/S4×-0.3×

Profitability

See full
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Current ratio2×-0.4×

Segments

By geography

See full
North America$59.0M+1.7%
Latin America$42.0M-23.6%
EMEA$31.0M+34.8%
Asia Pacific$4.0M+33.3%

By product

See full
Collaboration And Royalty$93.0M-9.7%
Royalty$47.0M-2.1%
Non Cash Royalty$20.0M+5.3%

Versus estimates

Revenue

Q1 2026$136.0MMiss by $22.2M
Q4 2025$207.0MBeat by $8.4MQ3 2025$159.9MMiss by $39.8MQ2 2025$166.5MBeat by $547.9KQ1 2025$139.3MMiss by $23.1MQ4 2024$164.9MBeat by $6.2M

Diluted EPS

Q1 2026-$1.84Miss by $0.35
Q4 2025-$1.29Miss by $0.09Q3 2025-$1.81Miss by $0.58Q2 2025-$1.17Beat by $0.10Q1 2025-$1.57Miss by $0.03Q4 2024-$1.39Miss by $0.07

Ask the moment Ultragenyx Pharmaceutical reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Ultragenyx Pharmaceutical report Q1 2026 earnings?
Ultragenyx Pharmaceutical (RARE) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Ultragenyx Pharmaceutical's Q1 2026 revenue and EPS?
Ultragenyx Pharmaceutical reported revenue of $136.0M and eps of $-1.84 for Q1 2026.
Did Ultragenyx Pharmaceutical beat estimates in Q1 2026?
Revenue missed the consensus estimate of $158.2M by $22.2M. EPS missed the consensus estimate of $-1.49 by $0.35.
How did Ultragenyx Pharmaceutical's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 2.4% from $139.3M a year earlier and eps declined 17.2% from $-1.57.
Where can I find Ultragenyx Pharmaceutical's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-206368) and the 10-Q periodic report (0001193125-26-206960) directly on SEC EDGAR. The filing index links above go to sec.gov.